Duncker Streett & Co. Inc. reduced its position in Bristol-Myers Squibb (NYSE:BMY) by 14.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 54,902 shares of the biopharmaceutical company’s stock after selling 8,987 shares during the period. Duncker Streett & Co. Inc.’s holdings in Bristol-Myers Squibb were worth $3,466,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Retirement Group LLC bought a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $27,000. Orion Capital Management LLC bought a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $28,000. Perennial Advisors LLC bought a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $29,000. Founders Capital Management bought a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $31,000. Finally, Brand Asset Management Group Inc. bought a new position in shares of Bristol-Myers Squibb during the first quarter worth about $31,000. 72.41% of the stock is owned by institutional investors.
Several equities research analysts recently weighed in on BMY shares. TheStreet upgraded shares of Bristol-Myers Squibb from a “c” rating to a “b” rating in a research note on Thursday, April 29th. Truist upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Tuesday, April 13th. Truist Financial upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Tuesday, April 13th. Truist Securities upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and increased their price objective for the stock from $66.00 to $74.00 in a research note on Monday, April 19th. Finally, Morgan Stanley lowered shares of Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $70.00 to $62.00 in a research note on Friday. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Buy” and an average target price of $73.81.
In related news, CEO Giovanni Caforio sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, March 22nd. The shares were sold at an average price of $62.20, for a total transaction of $1,555,000.00. Following the completion of the sale, the chief executive officer now directly owns 528,980 shares in the company, valued at $32,902,556. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.14% of the company’s stock.
NYSE BMY opened at $63.18 on Tuesday. Bristol-Myers Squibb has a 12 month low of $54.07 and a 12 month high of $67.16. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.67 and a quick ratio of 1.58. The firm has a market capitalization of $141.14 billion, a PE ratio of -577.04, a P/E/G ratio of 1.00 and a beta of 0.67. The company’s 50 day simple moving average is $63.60 and its 200 day simple moving average is $63.04.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Wednesday, April 28th. The biopharmaceutical company reported $1.74 EPS for the quarter, missing the Zacks’ consensus estimate of $1.82 by ($0.08). Bristol-Myers Squibb had a negative net margin of 0.11% and a positive return on equity of 27.48%. The company had revenue of $11.07 billion for the quarter, compared to analyst estimates of $11.19 billion. During the same quarter in the prior year, the business earned $1.72 EPS. Bristol-Myers Squibb’s revenue was up 2.7% compared to the same quarter last year. Sell-side analysts anticipate that Bristol-Myers Squibb will post 6.35 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Monday, May 3rd. Investors of record on Thursday, April 1st were issued a dividend of $0.49 per share. This represents a $1.96 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date was Wednesday, March 31st. Bristol-Myers Squibb’s payout ratio is 41.79%.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
Recommended Story: What are the Benefits of Index Funds?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.